CX-4945 (CX 4945) is a potent and selective ATP-competitive small molecule protein kinase CK2 inhibitor with a Ki and an IC50 of 0.38 and 1 nM for recombinant human CK2¦Á, respectively. CX-4945 (CX 4945) has broad spectrum anti-proliferative activity in multiple cancer cell lines. The antiproliferative activity of CX-4945 (CX 4945) against cancer cells correlated with expression levels of the CK2¦Á catalytic subunit. Attenuation of PI3K/Akt signaling by CX-4945 (CX 4945; Silmitasertib) was evidenced by dephosphorylation of Akt on the CK2-specific S129 site and the canonical S473 and T308 regulatory sites. CX-4945 (CX 4945) suppresses Akt signaling and inhibits proliferation of HUVEC Cells. CX-4945 (CX 4945) caused cell-cycle arrest and selectively induced apoptosis in cancer cells relative to normal cells. In models of angiogenesis, CX-4945 (CX 4945) inhibited human umbilical vein endothelial cell migration, tube formation, and blocked CK2-dependent hypoxia-induced factor 1 alpha (HIF-1¦Á) transcription in cancer cells. Collectively, CX-4945 (CX 4945) inhibits pro-angiogenic CK2 signaling in vitro and in vivo

June 21, 2017

prudect name : CX-4945 (CX 4945) is a potent and selective ATP-competitive small molecule protein kinase CK2 inhibitor with a Ki and an IC50 of 0.38 and 1 nM for recombinant human CK2¦Á, respectively. CX-4945 (CX 4945) has broad spectrum anti-proliferative activity in multiple cancer cell lines. The antiproliferative activity of CX-4945 (CX 4945) against cancer cells correlated with expression levels of the CK2¦Á catalytic subunit. Attenuation of PI3K/Akt signaling by CX-4945 (CX 4945; Silmitasertib) was evidenced by dephosphorylation of Akt on the CK2-specific S129 site and the canonical S473 and T308 regulatory sites. CX-4945 (CX 4945) suppresses Akt signaling and inhibits proliferation of HUVEC Cells. CX-4945 (CX 4945) caused cell-cycle arrest and selectively induced apoptosis in cancer cells relative to normal cells. In models of angiogenesis, CX-4945 (CX 4945) inhibited human umbilical vein endothelial cell migration, tube formation, and blocked CK2-dependent hypoxia-induced factor 1 alpha (HIF-1¦Á) transcription in cancer cells. Collectively, CX-4945 (CX 4945) inhibits pro-angiogenic CK2 signaling in vitro and in vivo
CX-4945

Synonyms: SilmitasertibCAS NO: 1009820-21-6Molecular Formula: C₁₉H₁₂ClN₃O₂Molecular Weight: 349.77Purity: 98% minSolubility: In DMSOStorage: −20°C

SCR-7 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18508995